Better Health for All

Spyre Therapeutics is a biotechnology company focused on developing long-acting antibodies and antibody combinations for inflammatory bowel disease (IBD) and rheumatic diseases.

Its entire business is devoted to health improvement, with a pipeline of investigational products in Phase 1 and Phase 2 clinical trials. The company is not currently commercial and does not place any products on the market for sale, resulting in no revenue from harmful products. Its lead product, SPY001, has been reported as well-tolerated in Phase 1 trials. Spyre adheres to internationally accepted principles for the ethical conduct of clinical trials, including GCP regulations, and requires appropriate ethical and scientific support for the involvement of vulnerable populations. The company provides an Employee Assistance Program through Cigna, offering up to three in-person counseling sessions per issue per year, and has annual programming for Mental Health Awareness month. It also provides stipends for ergonomic home office setups and reimburses gym memberships. However, the company's forward-looking statements include risks and uncertainties related to regulatory feedback and data inconsistencies, directing readers to SEC filings for further details, which suggests a standard, rather than exceptional, level of risk transparency. As a virtual company, 100% of its employees work remotely, which it states is its main way of mitigating environmental impact.

Fair Pay & Worker Respect

No specific, quantitative data points were found in the provided articles to assess the company against the defined KPIs for Fair Pay & Worker Respect. While the company has a Human Rights Policy committing to fair compensation, safe workplaces, and freedom of association,

and Glassdoor reviews mention 'great benefits' and 'robust employee programs', these are not quantitative metrics that map to the rubric's thresholds for living wage coverage, CEO-median pay ratio, collective bargaining share, safety incident rate, pay equity ratio, worker engagement score, turnover rate, labor violation incidents, insecure contract share, or health insurance coverage. The 83% headcount reduction in April 2023 was a restructuring, not a voluntary turnover metric.

Fair Trade & Ethical Sourcing

Spyre Therapeutics published a Code of Business Conduct and Ethics on December 12, 2024, and a Human Rights Policy on January 9, 2025.

These documents outline the company's commitment to ethical standards, fair treatment, equal opportunity, safe workplaces, and the prohibition of forced and child labor. They also detail reporting procedures for suspected violations, including an anonymous whistleblower hotline. The company states it outsources manufacturing and clinical trials to partners with strong environmental and social responsibility records and adheres to international ethical standards for clinical trials. However, no quantitative data was provided in the articles to assess specific metrics for fair trade and ethical sourcing.

Honest & Fair Business

Spyre Therapeutics has a formal whistleblower protection policy, established on February 1, 2024, which includes anonymous reporting options via a web form and a toll-free hotline.

Procedures are in place for handling reports of potential misconduct, with complaints involving the Chief Legal Officer directed to the Audit Committee and/or outside counsel. The company had one financial restatement covering 2023 and Q1-Q3 2024, with the amendment date being November 18, 2024. A Code of Business Conduct and Ethics, also dated February 1, 2024, explicitly addresses the Foreign Corrupt Practices Act (FCPA), prohibiting bribery and gifts to foreign officials, and provides guidance on 'expediting' payments. PricewaterhouseCoopers LLP serves as the independent registered public accounting firm.

Kind to Animals

Spyre Therapeutics is committed to using animals in research only when regulatory or scientific alternatives do not exist, and requires studies to be reviewed and approved by an animal welfare committee.

However, the company uses animals for preclinical testing of investigational antibodies, and a Yahoo Finance article states the company has significant involvement in animal testing. The company publicly discloses information about animals used in research, but does not provide specific numbers, indicating 50,000–100,000 animals are used annually. While Spyre has developed 'flycode technology' to reduce the number of laboratory animals used in preclinical studies, there is no specific percentage of the R&D budget allocated to animal-free technologies. The company's 'flycode technology' involved collaboration with multiple co-authors from different institutions, but there is no evidence of participation in multi-stakeholder initiatives to develop industry-wide animal-free testing standards. The company advocates for reducing animal use in research, but there is no evidence of active engagement in animal welfare policy improvement or advocacy for higher standards.

No War, No Weapons

Spyre Therapeutics, Inc. is a biotechnology company focused on developing antibody technologies for inflammatory bowel disease and rheumatoid arthritis.

The company's business is centered on research and development of monoclonal antibodies for medical treatments, with revenue primarily from license and development agreements. It is not a commercial entity and does not sell products. There is no evidence in the provided articles to suggest any involvement in arms manufacturing, military contracts, dual-use technologies, or conflict-related activities. Therefore, all KPIs related to the 'No War, No Weapons' value are assessed as not applicable to its core business operations.

Planet-Friendly Business

The provided articles consistently state a lack of specific, quantitative data for Spyre Therapeutics, Inc. (SYRE.US) regarding its environmental performance. Articles 0, 1, 4, and 5 explicitly mention that no relevant ESG metrics or quantitative data are available.

Article 5 further clarifies that as a non-commercial entity not yet selling products, the company does not have metrics related to product sales or environmental impact from production. While articles 0, 1, and 5 note that no regulatory actions, violations, fines, or compliance issues are mentioned, this is an absence of reporting within the articles rather than a concrete, verifiable statement of zero violations from the company itself, and thus does not meet the strict evidence criteria for scoring.

Safe & Smart Tech

Spyre Therapeutics reports no specific data breach incidents or unauthorized data use incidents.

The company conducts regular penetration and vulnerability testing, data recovery testing, security audits, and risk assessments. Its information security policy aligns with NIST security and privacy principles, and it states compliance with various privacy and data security laws, including HIPAA and CCPA. No quantitative data on cybersecurity investment, AI ethics, or specific metrics for security training effectiveness or user data control were provided.

Zero Waste & Sustainable Products

Spyre Therapeutics, Inc. operates virtually with all employees working remotely and outsources its manufacturing and clinical trials.

As a result, the company does not generate hazardous waste or handle substances of concern. The company does not currently manufacture or sell products, therefore no data is available for product-related waste metrics such as product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design principles, product durability, repairability, material efficiency, packaging-to-product ratio, or customer waste education. Information regarding waste diversion rates, waste reduction initiatives, waste audit frequency, zero-waste certifications, waste reduction targets, supplier waste requirements, or general waste disposal violations is also not provided.